SGMT — Sagimet Biosciences Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1400118 ·
Last close
$10.21
Market Cap
$628.85M
52W High
$11.15
52W Low
$6.24
ADV30
1,216,529
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,713,000 | -10,650,000 | 107,755,000 | 36,626,000 | 5,297,000 |
| Dec 2025 | 0 | — | -10,765,000 | -9,568,000 | 116,482,000 | 35,021,000 | 5,101,000 |
| Sep 2025 | 0 | — | -14,334,000 | -12,908,000 | 128,401,000 | 32,496,000 | 9,146,000 |
| Jun 2025 | 0 | — | -11,925,000 | -10,386,000 | 137,407,000 | 42,327,000 | 7,247,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-39,725,000
Investing CF
$11,359,000
Financing CF
$275,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.34
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-356,999,000
Inventory
—
Receivables
—
ST Investments
$67,913,000
EBIT TTM
$-48,737,000
Pretax Income TTM
$-43,512,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -56,889,000 | -51,038,000 | 116,482,000 | 5,101,000 | — | -45,650,000 |
| Dec 2024 | 0 | -54,454,000 | -45,567,000 | 160,259,000 | 4,454,000 | — | -42,435,000 |
| Dec 2023 | 2,000,000 | -30,740,000 | -27,876,000 | 96,719,000 | 5,654,000 | — | -23,766,000 |
| Dec 2022 | 0 | -31,055,000 | -30,499,000 | 33,031,000 | 219,981,000 | — | -24,490,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.34
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $10.21 · call volume: 39 · put volume: 60
Expected Move to 2026-09-18:
±$1.67
(16.36%) —
implied range
$8.54 –
$11.88
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CBIO | CRESCENT BIOPHARMA, INC. | $630.33M | $16.97 | — |
| VSTM | Verastem, Inc. | $621.27M | $6.86 | — |
| CRMD | CorMedix Inc. | $645.38M | $8.28 | — |
| ARVN | ARVINAS, INC. | $610.71M | $9.34 | — |
| ALT | Altimmune, Inc. | $604.95M | $3.11 | — |
News headlines (Yahoo Finance, 1h cache)
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-17 20:28 · Yahoo
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
2026-08-17 08:01 · Yahoo
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
2026-08-13 11:00 · Yahoo
Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says
2026-08-11 17:54 · Yahoo
Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion
2026-07-15 15:42 · Yahoo
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-06-23 00:49 · Yahoo
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
2026-06-04 13:55 · Yahoo
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
2026-05-27 11:00 · Yahoo
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
2026-05-21 13:55 · Yahoo
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-12 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.